Anticholinergic medication exposure predicts poor physical capability : Findings from a large prospective cohort study in England. by Yrjana, Kaisa R. et al.
Contents lists available at ScienceDirect
Maturitas
journal homepage: www.elsevier.com/locate/maturitas
Anticholinergic medication exposure predicts poor physical capability:
Findings from a large prospective cohort study in England
Kaisa R. Yrjanaa,b,1, Victoria L. Keevilc,d,e,1, Roy L. Soizaa,f, Robert N. Lubeng,
Nicholas J. Warehamh, Kay-Tee Khawg, Phyo K. Myinta,f,*
a Ageing Clinical & Experimental Research (ACER) Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
b Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
c Department of Medicine for the Elderly, Addenbrooke’s Hospital, Cambridge, UK
d Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK
e Department of Medicine, University of Cambridge, Cambridge, UK
fDepartment of Medicine for the Elderly, Aberdeen Royal Infirmary, Aberdeen, UK
g Department of Public Health & Primary Care University of Cambridge, Cambridge, UK
hMedical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK





A B S T R A C T
Objectives: To examine whether anticholinergic medication exposure in middle and late life is associated with
physical capability.
Study design: We used data from 8477 men and women who had enrolled in the European Prospective
Investigation of Cancer-Norfolk study at baseline (1HC; 1993–1997) and who had attended its third health
examination (3HC; 2004–2010). Medication history at the 1HC and 3HC was used to score participants ac-
cording to the Anticholinergic Cognitive Burden (ACB) Scale at baseline and 3HC; participants were categorised
as ACB=0, ACB=1, ACB>2.
Main outcome measure: At 3HC, physical capability was objectively measured by: usual walking speed, maximum
grip strength, timed chair stands speed (TCSS) and standing balance. Linear and logistic regression models
examined prospective and cross-sectional associations between ACB and physical capability, controlling for co-
morbidity, sociodemographic and lifestyle factors.
Results: The analyses included 3386 men and 4110 women who were 56.4 (SD 7.9) and 55.0 (7.7) years old
respectively at baseline and 69.4 (8.1) and 67.9 (8.0) years old at follow-up. Significant cross-sectional and
prospective relationships were observed for all physical capability measures in women, except grip strength. For
example, women with ACB≥ 2 compared with ACB=0 at baseline had 0.07m/s (95 % CI -0.11, -0.03) slower
usual walking speed, 2.61 stands/min (-4.17, -1.05) slower TCSS and higher odds of being unable to complete a
tandem stand (odds ratio 2.40, 95 % CI 1.53, 3.76). These trends were observed in men but were less consistent
in prospective analyses.
Conclusion: Exposure to anticholinergic medication predicts poor physical capability and is a potentially re-
versible risk factor.
1. Introduction
Many commonly prescribed medications such as anti-emetics, an-
tihistamines and tricyclic antidepressants are known to have antic-
holinergic properties. Approximately 20–50 % of older adults have a
prescription for at least one such medication and, in the UK, the pro-
portion of older people prescribed anticholinergic medications has
steadily increased over the last few years [1,2]. This trend is worrying
considering emerging evidence that anticholinergic medication ex-
posure is associated with adverse health outcomes. For example, ex-
posure to anticholinergic medications has been associated with late-life
cognitive impairment, higher risk of falls and incident stroke [3–5].
Physical capability refers to an individual’s ability to complete the
everyday activities of daily life. Objective measures of physical
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capability such as grip strength, usual walking speed, timed chair
stands speed (TCSS) and standing balance predict mortality, nursing
home admission and hospitalisation in older people [6,7]. The asso-
ciation between anticholinergic medication exposure and physical
capability has been previously explored [4,8–13] with studies demon-
strating a negative relationship. However, not all results have supported
an association between anticholinergic medication exposure and lower
physical capability, perhaps because studies have focused on older
patient groups with a limited age range and some have had small
sample sizes. Understanding the relationship between anticholinergic
medication use and physical capability is important, since this exposure
is prevalent and potentially modifiable. Additionally, preserving phy-
sical capability into late-life could improve the functional health of
older adults, reducing disability and dependency [14]. Therefore, the
aim of the current study is to explore the associations between antic-
holinergic medication exposure, as measured by the Anticholinergic
Cognitive Burden (ACB) Scale [15], and a range of objective measures
of physical capability in a large population-based sample of middle-
aged and older British men and women.
2. Methods
2.1. Participants
The participants used in this report were drawn from the European
Prospective Investigation of Cancer (EPIC)-Norfolk study, which re-
cruited 25 639 participants between the ages of 39 and 79 years from
general practice registers in and around the city of Norwich (Norfolk,
England) between 1993 and 1997. These participants attended a
baseline health examination (1HC) and the study design and follow-up
has been previously described [16]. The present study utilised data
from 8623 participants who also attended the 3rd health examination
(3HC) of the EPIC-Norfolk study [17]. During the 3HC, men and women
who were now aged 48–92 years old attended a central research clinic
and completed tests of physical performance and muscle strength.
Compared to those who took part in the 3HC, participants who did not
return were more likely to be from lower socioeconomic classes, older,
smokers and have had higher BMI and blood pressure at baseline [17].
Signed informed consent was obtained from the participants at baseline
and renewed at 3HC. Ethical approval was obtained from the Norfolk
Local Research Ethics Committee and the East Norfolk and Waveney
NHS Research Governance Committee.
2.2. Measurements
At the 1HC participants completed a health and lifestyle ques-
tionnaire and self-reported their educational status, social class, phy-
sical activity [18], smoking status, alcohol consumption, prevalent ill-
nesses and medication history. This assessment was repeated at the 3HC
using a similar questionnaire, although educational status and social
class were not ascertained again. Additionally, the 3HC health and
lifestyle questionnaire did not specifically ask about prevalent illnesses.
Therefore, in our analyses prevalent illness at the 3HC was estimated
using information combined from health and lifestyle questionnaires
administered at the 1HC and 3 years later at the second health ex-
amination (2HC 1998–2000). At both time points the prevalent illnesses
included in analyses were: myocardial infarction, stroke, cancer, dia-
betes, asthma, and arthritis. Information on depression requiring
treatment was available but was not included as a co-variable in re-
gression analyses due to multicollinearity.
Physiological parameters such as weight, and height were measured
by trained research nurses at a research clinic appointment at both the
1HC and 3HC. All measurements were made using standardised
equipment following standard operating procedures (SOPs).
Medications listed in the Anticholinergic Cognitive Burden (ACB)
scale [15] were cross-matched with the medication histories reported
by participants at both the 1HC and 3HC. The cross-matching process
identified exact or similar entries with respect to both the generic and
brand names of medications. Each medication was then assigned a
corresponding ACB scale score. Medications with no anticholinergic
properties i.e., no match, were scored 0. Medications with possible
anticholinergic effects were given a score of 1 and medications with
definite anticholinergic properties were given a score of 2 or 3, de-
pending on potency. The total ACB scale score was calculated as the
sum of all scores assigned to medications in each participant’s list at the
1HC and 3HC. Participants were then categorised according to their
total ACB scale score at the 1HC and 3HC: ACB=0, ACB=1 and
ACB≥ 2.
2.3. Outcome measures
Physical capability measures were collected by trained research
nurses at a central research clinic during the 3HC. 8477 participants
completed the physical capability assessment. Usual walking speed
(metres/second [m/s]) was estimated by calculating the average time
taken to walk a 4-metre course two times, with walking aids if neces-
sary. Grip strength was measured twice in each hand using a Smedley
dynamometer (Scandidact, Kvistgaard, Denmark) and the maximum
strength out of all attempts (Kilograms, Kg) was used in analyses. Timed
chair stands speed (TCSS, stands/minute) was measured by timing
participants as they rose from a chair five times. They were told to
perform the task as quickly as possible with their arms folded across
their chest and feet flat on the floor. Standing balance was recorded by
asking the participants to stand for 10 s with their feet apart in parallel,
semi-tandem and tandem positions. As reported previously, very few
members of the EPIC-Norfolk cohort were unable to complete the side-
by-side and semi-tandem stand [19]. Therefore, standing balance was
dichotomized into those who could and those who could not hold the
last standing test (tandem stand) for 10 s.
If participants were unable to take part in any of the physical cap-
ability tests for health reasons, or because they were unable to perform
the task, this was documented.
2.4. Statistical analysis
Statistical analyses were performed using SPSS version 24.0 (SPSS
Inc., Chicago, IL, USA). Sample characteristics and descriptive statistics
were presented at baseline and the 3HC by ACB scale categories.
Differences between ACB categories were assessed using the Chi-
squared test for categorical variables and analysis of variance (ANOVA)
for continuous variables. The associations between ACB categories and
grip strength, usual walking speed and TCSS were explored using linear
regression models, as data were normally distributed in these variables.
Associations between ACB category and standing balance were eval-
uated using logistic regression.
In supplementary analyses, logistic regression analyses were per-
formed to evaluate associations between ACB categories and poor grip
strength, defined as< 20 kg for women and<30 kg for men [20] and
poor gait speed, defined as< 1m/s for all participants [21]. Ad-
ditionally, logistic regression was used to evaluate associations between
those able versus unable to take part in the TCSS test (n= 794).
All of the analyses were performed separately for men and women
due to differences between sexes in physical capabilities. Multivariable
regression analyses were first adjusted for age and comorbidities (pre-
valent MI, stroke, cancer, diabetes, asthma, arthritis), Model A, and
then for social class and educational level, Model B. The effect of life-
style factors was explored individually with the following models:
Model C=B+ smoking status, Model D=B+alcohol intake, Model
E=B+body mass index (BMI) and Model F=B+physical activity.
Finally, model G adjusted for model B as well as all lifestyle factors
(smoking status, alcohol intake, BMI and physical activity). The ana-
lyses were performed prospectively, with predictors measured at
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baseline and outcomes at 3HC, as well as cross-sectionally with all
variables measured at the 3HC. F-Tests and Likelihood Ratio Tests were
used to compare models with and without anticholinergic burden and a
two-sided P-value< 0.05 was considered statistically significant.
Multivariable regression results were given as effect size (mean differ-
ence, ‘β' or odds ratio, OR) with 95 % Confidence Intervals (95 % CI).
3. Results
3.1. Characteristics of the EPIC-Norfolk population
3386 men and 4110 women who attended the 3HC, underwent
assessment of physical capability and had complete co-variable data
were included. The mean age (standard deviation, SD) of men at
baseline was 56.4 (7.9) years and 69.4 (8.1) years at follow up. The
corresponding values for women were 55.0 (7.7) years and 67.9 (8.0)
years, respectively.
Table 1 demonstrates the characteristics of the participants and
crude outcome values by ACB categories at the 3HC. Participants in the
higher ACB categories were older, had lower level of educational at-
tainment, higher BMI and increased prevalence of myocardial infarc-
tion, stroke and arthritis. Higher ACB category was also associated with
being physically inactive and lower physical capability. Similar trends
were observed between ACB categories and co-variables measured at
baseline and between ACB categories at baseline and physical cap-
ability measured over a decade later (Supplementary Data, Table 1).
The following sections explore associations between ACB categories
and physical capability using exposure and co-variable data both from
the 1HC (longitudinal analyses) and the 3HC (cross-sectional analyses).
3.2. Usual walking speed
In cross-sectional analyses, higher ACB category was independently
associated with slower usual walking speed and the association ex-
hibited a dose-response relationship in both men and women (Table 2).
For example, men with an ACB score of 1 and > 2 had a 0.03m/s (95
% CI -0.05, -0.01) and 0.07m/s (95 % CI -0.10, -0.01) slower usual
walking speed respectively, compared to men who took no antic-
holinergic medication. Associations persisted in prospective analyses
although were weaker in men. The odds of participants having poor
usual walking speed (< 1m/s) by ACB category are shown in Supple-
mentary Data, Table 2. In cross-sectional analyses, participants with
higher ACB scale scores had higher odds of slow usual walking speed
(Men: ACB=1, OR 1.43, 95 % CI 1.1, 1.78; ACB>2, OR 1.60, 95 % CI
1.22, 2.11; Women: ACB=1, OR 1.29, 95 % CI 1.05, 1.58; ACB≥ 2 OR
1.78 95 % CI1.43, 2.22). In prospective analyses, women with higher
ACB scale scores at baseline were more likely to have slow usual
walking speed at the 3HC (ACB=1: OR 1.46, 95 % CI 1.07, 2.00;
ACB≥ 2: OR 2.15, 95 % CI 1.47, 3.14), while no significant association
between ACB category at baseline and odds of poor usual walking speed
were observed in men.
3.3. Grip strength
Higher ACB category was associated with weaker grip strength in a
dose-response manner, but only in cross-sectional analyses (Table 3).
Table 1
Characteristics of the 7496 men and women at the 3HC.
Men (n= 3386) Women (n= 4110)












Age, years 68.4 (8.0) 72.0 (7.4) 69.4 (8.1)* 67.1 (8.0) 72.0 (7.4) 73.4 (7.6)*
BMI, kg/m2 26.8 (3.4) 27.8 (3.9) 27.7 (3.7)* 26.1 (4.5) 27.3 (5.0) 28.1 (5.0)*
MI, n (%) 68 (2.7) 61 (11.5) 46 (15.4)* 24 (0.8) 26 (4.5) 25 (5.3)*
Stroke, n (%) 46 (1.8) 31 (5.8) 24 (8.0)* 29 (0.9) 11 (1.9) 18 (3.8)*
Cancer, n (%) 168 (6.6) 42 (7.9) 39 (13.0)* 327 (10.7) 69 (12.0) 49 (10.4)
Diabetes, n (%) 76 (3.0) 31 (5.8) 22 (7.4)* 51 (1.7) 26 (4.5) 16 (3.4)*
Asthma (%) 261 (10.2) 60 (11.3) 40 (13.4) 362 (11.8) 82 (14.2) 86 (18.3)*
Arthritis, n (%) 727 (28.4) 181 (34.1) 133 (44.5)* 1140 (37.2) 292 (50.6) 260 (55.4)*
Depression, n (%) 301 (11.8) 98 (18.5) 71 (23.7) 776 (25.3) 172 (29.8) 199 (42.4)*
Social class, n (%)
Professional 259 (10.1) 50 (9.4) 23 (7.7) 276 (9.0) 42 (7.3) 33 (7.0)
Manager 1114 (43.6) 224 (42.2) 132 (44.1) 1250 (40.8) 208 (36.0) 201 (42.9)
Skilled non-manager 319 (12.5) 56 (10.5) 42 (14.0) 566 (18.5) 119 (20.6) 84 (17.9)
Skilled manual 561 (21.9) 116 (21.8) 67 (22.4) 581 (19.0) 124 (21.5) 71 (15.1)
Semi-skilled 255 (10.0) 71 (13.4) 31 (10.4) 330 (10.8) 59 (10.2) 63 (13.4)
Unskilled 48 (1.9) 14 (2.6) 4 (1.3) 61 (2.0) 25 (4.3) 17 (3.6)*
Education level, n (%)
No qualifications 520 (20.3) 147 (27.7) 71 (23.7) 812 (26.5) 206 (35.7) 166 (35.4)
O level 271 (10.6) 44 (8.3) 24 (8.0) 418 (13.6) 70 (12.1) 64 (13.6)
A level 1209 (47.3) 255 (48.0) 150 (50.2) 1304 (42.6) 222 (38.5) 181 (38.6)
Higher degree 556 (21) 85 (16.0) 54 (18.1)* 530 (17.3)* 79 (13.7) 58 (12.4)*
Smoking status, n (%)
Current 110 (4.3) 16 (3.0) 11 (3.7) 131 (4.3) 37 (6.4) 18 (3.8)
Ex-smoker 1413 (55.3) 347 (65.3) 197 (65.9) 1084 (35.4) 229 (39.7) 193 (41.2)
Never smoker 1033 (40.4) 168 (31.6) 91 (30.4)* 1849 (60.3) 311 (53.9) 258 (55.0)#
Alcohol use, units/week 8.8 (10.3) 7.0 (7.9) 7.7 (9.6)* 4.5 (5.8) 3.4 (4.9) 3.7 (5.8)*
Physical activity, n (%)
Inactive 860 (33.6) 238 (44.8) 154 (51.5) 1006 (33.2) 265 (45.9) 224 (47.8)
Moderately inactive 642 (25.1) 138 (26.0) 76 (25.4) 1017 (33.2) 188 (32.6) 124 (26.4)
Moderately active 519 (20.3) 88 (16.6) 41 (13.7) 559 (18.2) 76 (13.2) 74 (15.8)
Active 535 (20.9) 67 (12.6) 28 (9.4)* 482 (15.7) 48 (8.3) 47 (10.0)*
UWS, m/s 1.2 (0.2) 1.1 (0.2) 1.0 (0.3)* 1.1 (0.2) 1.0 (0.3) 1.0 (0.3)*
Grip strength, Kg 40.0 (8.2) 37.4 (7.9) 36.1 (7.7)* 24.9 (5.3) 23.4 (5.4) 22.9 (5.9)*
TCSS, stands/min 27.5 (8.4) 25.4 (7.9) 23.5 (7.3)* 26.7 (8.7) 24.2 (7.6) 24.1 (7.7)*
Standing balance, n able (%) 2208 (94.1) 410 (90.5) 199 (84.7)* 2738 (89.4) 475 (82.3) 349 (74.4)*
*P < 0.001; #P< 0.05; BMI: Body mass index; MI: myocardial infarction; UWS: usual walking speed; TCSS: Timed Chair Stands Speed.
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For example, ACB≥ 2 was associated with a 1.16 kg weaker grip
strength (95 % CI -2.02, -0.30) in men and 0.96 kg weaker grip strength
in women (95 % CI -1.44, -0.47). No prospective associations between
ACB category and grip strength were observed. The odds of participants
having poor grip strength according to ACB category were also assessed
(Supplementary Table 3). No strong or consistent associations were
found and the only cross-sectional associations in women were sig-
nificant..
3.4. Timed chair stand speed (TCSS)
Higher ACB category was associated with slower TCSS in the 6702
participants who completed this test (Table 4). Cross-sectionally,
ACB≥ 2 was associated with 1.79 stands/min (95 % CI -2.84,-072) and
0.96 stand/min (95 % CI 1.85, -0.08) slower TCSS for men and women
respectively compared to those who had an ACB scale score of zero. In
prospective analyses, women in the ACB≥ 2 group had on average
2.61 stands/min (95 % CI -4.17, -1.05) slower TCSS compared to those
in the ACB=0 category, while men with ACB=1 had 1.58 stands/min
(95 % CI -2.74, -0.43) slower TCSS compared to those in the ACB=0
category.
Higher ACB category was also associated with inability to partici-
pate in the TCSS test due to poor functional ability or health reasons
(Supplementary Data, Table 4). In men, significant associations were
only observed in cross-sectional analyses, whilst both cross-sectional
and prospective associations were observed in women. For example,
baseline ACB category was independently associated with higher odds
of women being unable to participate in the TCSS test at the 3HC
(ACB=1 OR 1.93, 95 % CI 1.34, 2.77; ACB≥ 2 OR 1.81, 95 % CI 1.13,
2.89).
3.5. Standing balance
ACB category was associated with poor standing balance in both
cross-sectional and prospective analyses for women (Table 5). The as-
sociation also exhibited a dose-response relationship. For example,
baseline ACB category was associated with higher odds of being unable
to perform a tandem stand (ACB=1 OR of 1.69, 95 % CI 1.17, 2.42;
ACB≥ 2 OR of 2.40, 95 % CI 1.53, 3.76). For men, associations did not
persist in prospective analyses (Table 5).
4. Discussion
To our knowledge this is the first study to investigate the association
between anticholinergic medication exposure and physical capability in
a cohort of men and women spanning a wide age-range, originally
sampled from the general population. Our results demonstrate that
anticholinergic burden was significantly associated with poorer usual
walking speed, standing balance and performance in the TCSS test in
both cross-sectional and prospective analyses, with evidence of a dose-
response association. In prospective analyses associations were stronger
and more consistent in women and, in either sex, ACB category was
only associated with low grip strength in cross-sectional analyses.
A clinically meaningful change in usual walking speed has been
estimated at around 0.5m/s with differences of 0.10m/s associated
with significant differences in mortality risk [22,23]. Our results were
comparable to this magnitude, especially in women, and the differences
observed in walking speed across ACB categories were equivalent to
between 3 and 9 years difference in age [19]. To the best of our
knowledge, other physical capability measures investigated in this
study do not have well-defined clinically relevant change values but
associations between lower physical capability and higher mortality
have been described with a 1 kg difference in grip strength [24] and
being unable to hold a tandem stand [25]. Additionally, low grip
Table 3
Maximum grip strength (kg) by ACB category in men and women at the third health examination (3HC) and first health examination (1CH).
Regression Coefficient (95 % Confidence Interval)
Model A Model B Model C Model D Model E Model F Model G
Men (n=3386)
3HC
ACB=0 0 0 0 0 0 0 0
ACB=1 −0.64 (-1.31, 0.03) −0.65 (-1.32,
0.02)




















ACB=0 0 0 0 0 0 0 0
ACB=1 −0.10 (-1.05, 0.86) −0.10 (-1.06,
0.85)
−0.14 (-1.10, 0.81) −0.11 (-1.06, 0.85) −0.32 (-1.27,
0.63)
−0.08 (-1.03, 0.88) −0.31 (-1.26, 0.64)
ACB≥ 2 0.44 (-1.12, 2.01) 0.35 (-1.22, 1.91) 0.39 (-1.18. 1.91) 0.35 (-1.22, 1.91) 0.22 (-1.34, 1.77) 0.34 (-1.23, 1.90) 0.70 (-1.30, 1.80)
WOMEN (n=4110)
3HC
ACB=0 0 0 0 0 0 0 0
ACB=1 −0.41 (-0.85, 0.03) −0.35 (-0.79,
0.09)
−0.39 (-0.83, 0.06) −0.34 (-0.78, 0.10) −0.46 (-0.90,
-0.01)
−0.28 (-0.72, 0.17) −0.42 (-0.86, 0.03)















ACB=0 0 0 0 0 0 0 0
ACB=1 −0.43 (-1.14, 0.27) −0.43 (-1.13,
0.27)
−0.45 (-1.15, 0.25) −0.42 (-1.12, 0.28) −0.52 (-1.44,
0.15)
−0.35 (-1.05, 0.35) −0.45 (-1.15, 0.25)
ACB≥ 2 −0.41 (-0.85, 0.03) −0.35 (-0.79,
0.09)
−0.39 (-0.83, 0.06) −0.34 (-0.78, 0.10) −0.41 (-0.94,
0.35)
−0.27 (-1.13, 0.59) −0.34 (-1.20, 0.51)
* = p < 0.001 **=p<0.01 #= p < 0.05 (F Test or Likelihood Ratio Test used to compare models with and without ACB). Regression coefficients represent the
differences in maximum grip strength (kg) between ACB=1 or ACB=2 and ACB=0 (reference category). 1HC: first health examination; 3HC: third health
examination. Model A: adjusted for age and comorbidities (MI, stroke, cancer, diabetes, asthma, arthritis), Model B: adjusted for A and environmental factors (social
class, educational level) Model C: B+ smoking, Model D: B+ alcohol, Model E: B+body mass index (BMI), Model F: B+ physical activity (PA), Model G:
B+ smoking, alcohol intake, BMI and PA (the fully adjusted model).
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strength and slow walking speed, as defined in our supplementary
analyses, are associated with higher risk of adverse health outcomes
[20,21]. Therefore, the differences in physical capability, and odds of
poor physical capability, observed across ACB categories were mean-
ingful.
Physical capability is also a meaningful outcome to study. Mid and
late-life physical capability predicts important health outcomes such as
mortality, institutionalisation, and the onset of disability [24,25].
Physical capability has also been suggested as a possible mediating
factor in relationships between anticholinergic medication exposure
and health outcomes such as falls [4]. Therefore, identifying factors
that are associated with lower physical capability is important since this
will inform development of future interventions targeted at improving
health in later life. For example, anticholinergic medication exposure is
a prevalent and potentially modifiable risk factor. Commonly pre-
scribed anticholinergic medications for conditions such as itch or de-
pression could be substituted with alternative therapies with less or no
anticholinergic properties, if this change was associated with health
benefits.
Previous literature exploring associations between anticholinergic
medication exposure and physical function has focused on populations
of older adults who are generally > 65 years old [4,8–13]. Studies have
also been limited by small sample sizes [4,10,12,13] and have used a
range of assessment tools to measure anticholinergic medication ex-
posure, some of which have not been well validated [8,12]. For ex-
ample, a study of 88 community dwelling older adults (mean age 72)
measured serum anticholinergic activity and linked this to slower gait
speed [13]. A study of 932 moderately to severely disabled community-
dwelling older women (>65 years) demonstrated anticholinergic
medication exposure, assessed using a novel scale, to be associated with
higher odds of slow gait speed, poor balance, poor chair stands per-
formance and weak grip strength [8]. Another study of frail elderly
(n=364, aged >80) used a novel scale to measure anticholinergic
medication exposure and linked higher exposure to impaired grip
strength and poorer performance in the Short Physical Performance
Battery (based on walking speed, balance, and chair stand tests) [12]. A
recent case-control study investigating falls on 428 community
dwelling older adults (mean age 74) found anticholinergic medication
exposure measured with the ACB scale to be significantly associated
with poorer dynamic balance and gait speed, but not grip strength, si-
milar to our longitudinal results [4].
Three studies have previously examined the association of Drug
Burden Index (DBI) and physical function [9–11]. All three reported
DBI to be associated with slower gait speed in older people. However,
only one of them reported the effects of the anticholinergic component
of the DBI separately. In this study of older Australian men, the antic-
holinergic part of the DBI was associated with weak grip strength only
and not TCSS, usual walking speed or standing balance in contrast to
our results [9].
In the prospective analyses, ACB category was demonstrated to
predict slower gait speed, standing balance and TCSS performance, but
not grip strength. This could indicate that anticholinergic medication
exposure affects physical capability not by reducing overall strength,
but by acting in the central nervous system (CNS) areas responsible for
movement control and balance, something previously suggested by Zia
et al. [4]. For example, the Basal Ganglia is a brain area highly involved
in movement control and has a high density of cholinergic neurons
[26]. Furthermore, most medications with anticholinergic properties
are non-selective antagonists of muscarinic acetylcholine receptors [27]
and all five muscarinic receptor subtypes are expressed in the brain
[28]. Therefore, given the broad distribution of muscarinic receptors in
the CNS and the high density of cholinergic neurones in areas important
for movement control, such as the basal ganglia, anticholinergic med-
iations could mediate their effects on physical capability via CNS ac-
tion.
Our study has several strengths. We used a well validated scale to
measure the anticholinergic burden. We also utilised the infrastructure
of a large prospective population-based cohort study, which allowed us
to capture a sufficient number of participants with high ACB scores to
power analyses. The wide age range of the cohort which includes both
men and women also improves the generalizability of our results. We
were also able to perform both cross-sectional and prospective analyses
and control for variety of lifestyle and sociodemographic factors as well
as comorbidities.
We also have some limitations. EPIC-Norfolk is a prospective cohort
study that was similar to other UK representative population samples at
baseline [16]. However, it is possible that attrition bias could have been
introduced due to the 10- to 15-year length of the study with only 8623
Table 5
Odds of participants being unable to hold tandem stand for 10 s by ACB scale category at the third health examination (3HC) and first health examination (1CH).
Odds ratios (95 % Confidence Interval)#
Model A Model B Model C Model D Model E Model F Model G
Men (n=3386)
3HC
ACB=0 1.00 1.00 1.00 1.00 1.00 1.00 1.00
ACB=1 1.26 (0.93, 1.72) 1.27 (0.93, 1.72) 1.26 (0.93, 1.72) 1.27 (0.93, 1.72) 1.17 (0.85, 1.60) 1.24 (0.91, 1.70) 1.15 (0.84, 1.58)
ACB≥ 2 1.98 (1.41, 2.77)* 2.00 (1.42, 2.81)* 2.00 (1.42, 2.80)* 2.00 (1.42, 2.80)* 1.90 (1.35, 2.67)* 1.95 (1.38, 2.74)* 1.85 (1.31, 2.61)*
1HC
ACB=0 1.00 1.00 1.00 1.00 1.00 1.00 1.00
ACB=1 1.33 (0.91, 1.97) 1.32 (0.90, 1.95) 1.32 (0.90, 1.96) 1.32 (0.90, 1.96) 1.27 (0.86, 1.87 1.29 (0.87, 1.91) 1.30 (0.86, 1.96)
ACB≥ 2 1.39 (0.71, 2.69) 1.35 (0.69, 2.63) 1.35 (0.69, 2.63) 1.35 (0.69, 2.63) 1.32 (0.68, 2.58) 1.34 (0.69, 2.62) 1.18 (0.57, 2.45)
Women (n=4110)
3HC
ACB=0 1.00 1.00 1.00 1.00 1.00 1.00 1.00
ACB=1 1.29 (1.0, 1.68) 1.24 (0.95, 1.61) 1.23 (0.94, 1.60) 1.24 (0.95, 1.61) 1.16 (0.89, 1.51) 1.20 (0.92, 1.57) 1.13 (0.86, 1.47)
ACB≥ 2 2.20 (1.70, 2.84)* 2.14 (1.65, 2.77)* 2.14 (1.65, 2.77)* 2.14 (1.65, 2.78)* 1.94 (1.49, 2.52)* 2.08 (1.60, 2.70)* 1.90 (1.46, 2.48)*
1HC
ACB=0 1.00 1.00 1.00 1.00 1.00 1.00 1.00
ACB=1 1.75 (1.23, 2.49) 1.79 (1.26, 2.53) 1.79 (1.26, 2.54) 1.79 (1.26, 2.53) 1.68 (1.18, 2.39) 1.74 (1.22, 2.47) 1.69 (1.17, 2.42)
ACB≥ 2 2.78 (1.83, 4.21)* 2.61 (1.71, 4.0)* 2.58 (1.69, 3.93)* 2.61 (1.72, 4.0)* 2.49 (1.64, 3.81)* 2.56 (1.68, 3.88)* 2.40 (1.53, 3.76)*
* = p < 0.001 **=p<0.01 #= p < 0.05 (F Test or Likelihood Ratio Test used to compare models with and without ACB). Odds ratios represent the odds of
being unable to hold a tandem stand for 10 s in ACB=1 or ACB=2 categories compared to the reference category, ACB=0. 1HC: first health examination; 3HC:
third health examination. Model A: adjusted for age and comorbidities (MI, stroke, cancer, diabetes, asthma, arthritis), Model B: adjusted for A and environmental
factors (social class, educational level) Model C: B+ smoking, Model D: B+ alcohol, Model E: B+ body mass index (BMI), Model F: B+ physical activity (PA),
Model G: B+ smoking, alcohol intake, BMI and PA (the fully adjusted model).
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out of the original 25,000 participants returning for the 3HC [17].
Additionally, we could not control for all potential confounders e.g.,
prevalent illness was incompletely ascertained at the 3HC. Therefore,
some participants could have developed important co-morbidities im-
pacting on their physical capability e.g., arthritis that we did not
completely capture at the 3HC because we were relying on information
collected at earlier time points (the 1HC and 2HC). Although we were
able to calculate the total ACB scale score, we were not able to identify
whether particular drugs or dosages were linked to physical capability
or whether any associations observed were ubiquitous across all med-
ications with anticholinergic properties. If ubiquitous, this would
strengthen evidence that associations were unlikely to be due to a
particular underlying health condition for which the medication was
prescribed. Finally, associations were stronger and more consistent in
women than men in prospective analyses. This could be due to phy-
siological differences between sexes but it should also be noted that
there were fewer men in analyses, particularly in the highest ACB ca-
tegory at the 1HC, reducing power.
5. Conclusion
The use of anticholinergic medications predicts poor physical cap-
ability in the EPIC-Norfolk population. The association between ACB
category and objective measures of functional performance remained
significant after adjusting for various potential confounders. Our study
adds to the growing evidence that suggests clinicians should prescribe
drugs with anticholinergic properties with caution. Future studies
should explore the effect of reduction in anticholinergic medication
prescribing on physical capability.
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